RESUMO
OBJECTIVES: To retrospectively evaluate the disease free survival (DFS),disease specific survival (DSS),overall survival (OS) and side effects in patients who received low-dose rate (LDR) brachytherapy with I125 stranded seeds. MATERIALS AND METHODS: Between july 2003 and august 2012, 274 patients with organ confined prostate cancer were treated with permanent I125 brachytherapy. The median follow-up, age and pretreatment prostate specific antigen (iPSA) was 84 months (12-120), 67 years (50-83) and 7.8 ng/mL (1.14-38), respectively. Median Gleason score was 6 (3-9). 219 patients (80%) had stage cT1c, 42 patients (15.3%) had stage cT2a, 3 (1.1%) had stage cT2b and 3 (1.1%) had stage cT2c. The median D90 was 154.3 Gy (102.7-190.2). RESULTS: DSS was 98.5%.OS was 93.5%. 13 patients (4.7%) developed systemic disease, 7 patients (2.55%) had local progression. In 139 low risk patients, the 5 year biochemical freedom from failure rate (BFFF) was 85% and 9 patients (6.4%) developed clinical progression. In the intermediate risk group, the 5 year BFFF rate was 70% and 5 patients (7.1%) developed clinical progression. Median nPSA in patients with biochemical relapse was 1.58 ng/mL (0.21 - 10.46), median nPSA in patients in remission was 0.51 ng/mL (0.01 - 8.5). Patients attaining a low PSA nadir had a significant higher BFFF (p<0.05). Median D90 in patients with biochemical relapse was 87.2 Gy (51 - 143,1). Patients receiving a high D90 had a significant higher BFFF (p<0.05). CONCLUSION: In a well selected patient population, LDR brachytherapy offers excelente outcomes. Reaching a low PSA nadir and attaining high D90 values are significant predictors for a higher DFS.
Assuntos
Braquiterapia/efeitos adversos , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/efeitos adversos , Neoplasias da Próstata/radioterapia , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta à Radiação , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Prognóstico , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/patologia , Reto/efeitos da radiação , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Fatores de Tempo , Uretra/efeitos da radiação , Bexiga Urinária/efeitos da radiaçãoRESUMO
INTRODUCTION: Traditionally, the body mass index (BMI) is used to describe anthropometric measurements and to assess weight-related health risks. However, the abdominal circumference (AC) might also be a valuable parameter to estimate this risk. This study aims to describe an association between the BMI and the AC. MATERIAL AND METHODS: Participants were recruited during the Brussels Food Fair in 2014. They completed a questionnaire with their medical history, and health related parameters such as blood pressure, weight, height and AC were measured. RESULTS: In total, 705 participants were analyzed. Men had a mean BMI of 27.3 kg/m2 and a mean AC of 98.7 cm. Women had a mean BMI of 26.0 kg/m2 and a mean AC of 88.2 cm. The Pearson's correlation coefficient between the BMI and the AC was 0.91 for men and 0.88 for women. There was a strong positive correlation between the BMI and the AC. In the identification of patients at high risk for weight-related diseases, the use of the AC identified more patients than the BMI. Especially more women were ranking in a higher risk class with the AC than with the BMI classification. Both the BMI as well as the AC identified most diseases with an increased relative risk. CONCLUSION: There is a strong correlation between the BMI and the AC. There are too few arguments to prefer the use of AC above the BMI to detect people at high risk for weight-related diseases.
Assuntos
Tecido Adiposo/patologia , Índice de Massa Corporal , Obesidade/patologia , Circunferência da Cintura , Abdome , Adulto , Idoso , Bélgica/epidemiologia , Composição Corporal , Estatura , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/epidemiologia , Obesidade/metabolismo , Prevalência , Valores de Referência , Medição de Risco , Fatores de Risco , Inquéritos e QuestionáriosRESUMO
ABSTRACT Objectives: To retrospectively evaluate the disease free survival (DFS), disease specific survival (DSS),overall survival (OS) and side effects in patients who received low-dose rate (LDR) brachytherapy with I125 stranded seeds. Materials and methods: Between july 2003 and august 2012, 274 patients with organ confined prostate cancer were treated with permanent I125 brachytherapy. The median follow-up, age and pretreatment prostate specific antigen (iPSA) was 84 months (12-120), 67 years (50-83) and 7.8 ng/mL (1.14-38), respectively. Median Gleason score was 6 (3-9). 219 patients (80%) had stage cT1c, 42 patients (15.3%) had stage cT2a, 3 (1.1%) had stage cT2b and 3 (1.1%) had stage cT2c. The median D90 was 154.3 Gy (102.7-190.2). Results: DSS was 98.5%.OS was 93.5%. 13 patients (4.7%) developed systemic disease, 7 patients (2.55%) had local progression. In 139 low risk patients, the 5 year biochemical freedom from failure rate (BFFF) was 85% and 9 patients (6.4%) developed clinical progression. In the intermediate risk group, the 5 year BFFF rate was 70% and 5 patients (7.1%) developed clinical progression. Median nPSA in patients with biochemical relapse was 1.58 ng/mL (0.21 – 10.46), median nPSA in patients in remission was 0.51 ng/mL (0.01 – 8.5). Patients attaining a low PSA nadir had a significant higher BFFF (p<0.05). Median D90 in patients with biochemical relapse was 87.2 Gy (51 – 143,1). Patients receiving a high D90 had a significant higher BFFF (p<0.05). Conclusion: In a well selected patient population, LDR brachytherapy offers excellent outcomes. Reaching a low PSA nadir and attaining high D90 values are significant predictors for a higher DFS.